C.R. Bard (BCR) & Sientra (SIEN) Financial Review

C.R. Bard (NYSE: BCR) and Sientra (NASDAQ:SIEN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for C.R. Bard and Sientra, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
C.R. Bard 0 7 0 0 2.00
Sientra 0 1 4 0 2.80

C.R. Bard currently has a consensus target price of $295.43, suggesting a potential downside of 11.05%. Sientra has a consensus target price of $13.75, suggesting a potential upside of 6.26%. Given Sientra’s stronger consensus rating and higher probable upside, analysts plainly believe Sientra is more favorable than C.R. Bard.

Risk & Volatility

C.R. Bard has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Sientra has a beta of -1.47, meaning that its share price is 247% less volatile than the S&P 500.

Profitability

This table compares C.R. Bard and Sientra’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
C.R. Bard 14.75% 48.28% 16.23%
Sientra -169.77% -68.82% -43.13%

Institutional and Insider Ownership

79.2% of C.R. Bard shares are held by institutional investors. Comparatively, 76.6% of Sientra shares are held by institutional investors. 0.8% of C.R. Bard shares are held by company insiders. Comparatively, 28.1% of Sientra shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dividends

C.R. Bard pays an annual dividend of $1.04 per share and has a dividend yield of 0.3%. Sientra does not pay a dividend. C.R. Bard pays out 13.7% of its earnings in the form of a dividend. C.R. Bard has raised its dividend for 45 consecutive years.

Earnings and Valuation

This table compares C.R. Bard and Sientra’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
C.R. Bard $3.71 billion 6.52 $531.40 million $7.59 43.76
Sientra $20.73 million 12.11 -$40.16 million ($2.85) -4.54

C.R. Bard has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than C.R. Bard, indicating that it is currently the more affordable of the two stocks.

Summary

C.R. Bard beats Sientra on 10 of the 16 factors compared between the two stocks.

About C.R. Bard

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

About Sientra

Sientra, Inc. is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.